Monthly Intravitreal Infliximab in Behçet’s Disease Active P
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
To study the safety of extended monthly intravitreal infliximab injections in patients with active posterior uveitis in Behcet’s disease (APUBD) a study was conducted. This is a prospective, interventional, noncomparative, open-label, pilot study of 9 monthly intravitreal infliximab injections (1mg/0.05ml) for twenty-two eyes of 16 patients with active posterior uveitis in Behcet’s disease. Control of inflammation and visual outcomes were assessed, and ocular complications were monitored during the study period.

Successful treatment was achieved in 7 eyes (35%) and failure was encountered in 13 eyes (65%). Only seven eyes of 6 patients (35%) had completed the study and achieved complete resolution of inflammation with improved BCVA, and no complications. Failure was either due to inability to control the inflammation in 9 eyes (45%) or development of exacerbation of inflammation in 4 eyes (20%). Four eyes developed severe immunological reactions from the drug following first, second, and third injections and had to discontinue the injections. Kaplan-Meier survival analysis showed that the mean estimated time to failure was 3.3±0.2 months and all failed eyes required revision of their systemic immunotherapy to control the ocular inflammation. Intravitreal infliximab for active posterior uveitis in Behcet’s disease was associated with a high complication rate and failure to control inflammation in the majority of eyes. It should not be considered a substitute for systemic therapy.

Source:https://journals.lww.com/retinajournal/Abstract/9000/Monthly_Intravitreal_Infliximab_in_Beh_et_s.95607.aspx
Like
Comment
Share